ALLR.US Allarity Therapeutics Inc

Healthcare Biotechnology USA Stocks
0.9538 USD
Close of Nov 14, 2026
0.7687 1.84
Market cap
USD 15.2M
P/E
-
P/B
4.11x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ALLR.US undervalued?

Graham number

The Graham number of Allarity Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Allarity Therapeutics Inc fundamental analysis

No fundamental analysis for Allarity Therapeutics Inc yet.

Allarity Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Allarity Therapeutics Inc

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PAR…

Full company profile